Lastly, although RB1 and TP53 mutations are uncommon in well/dedifferentiated liposarcoma, these alterations confer resistance to palbociclib (CDK4/6) and MDM2 inhibitors, respectively71,65. Here, MDM2 is linked to liposarcoma.